I.v. immunoglobulins ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 151 | Rasmussen encephalitis | 1 |
151. Rasmussen encephalitis
Clinical trials : 2 / Drugs : 4 - (DrugBank : 2) / Drug target genes : 6 - Drug target pathways : 86
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00545493 (ClinicalTrials.gov) | November 2002 | 16/10/2007 | Efficacy of Tacrolimus and I.V.-Immunoglobulins in Rasmussen Encephalitis | Efficacy of Tacrolimus and i.v.-Immunoglobulins in Rasmussen Encephalitis With Start of Treatment in the Acute Disease Stage. Prospective, Randomised, Open Parallel Group Study | Rasmussen Encephalitis | Drug: Tacrolimus;Drug: i.v. immunoglobulins | University Hospital, Bonn | Octapharma;Astellas Pharma GmbH | Active, not recruiting | N/A | N/A | Both | 16 | Phase 2/Phase 3 | Germany |